Claims for Patent: 8,647,842

Summary for Patent: 8,647,842

Title:	Methods for producing a fusion protein capable of binding VEGF
Abstract:	The present invention provides methods for producing a fusion protein capable of binding vascular endothelial cell growth factor (VEGF). The methods of the invention comprise growing recombinant cells in suspension culture, wherein the recombinant cells contain an expression vector comprising a nucleic acid molecule encoding a fusion protein that binds VEGF, and isolating the fusion protein from the suspension culture. The fusion protein may comprise a VEGF receptor component having an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor, an Ig domain 3 of a second VEGF receptor, and a multimerizing component.
Inventor(s):	Papadopoulos; Nicholas J. (Lagrangeville, NY), Davis; Samuel (New York, NY), Yancopoulos; George D. (Yorktown Heights, NY)
Assignee:	Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Application Number:	13/439,889
Patent Claims:	1. A method for producing a fusion protein capable of binding VEGF, the method comprising: (a) growing recombinant cells in suspension culture, wherein the recombinant cells contain an expression vector comprising a nucleic acid molecule that encodes a fusion protein selected from the group consisting of Flt1D2.Flk1D3.Fc.DELTA.C1(a) (SEQ ID NO:12) and VEGFR1R2-Fc.DELTA.C1(a) (SEQ ID NO:16); and (b) isolating the fusion protein from the suspension culture. 2. The method of claim 1, wherein the isolating step (b) comprises isolating the fusion protein from the suspension culture by affinity chromatography, followed by size-exclusion chromatography. 3. The method of claim 1, wherein the recombinant cells are E. coli cells, COS cells or CHO cells. 4. The method of claim 1, wherein the recombinant cells are CHO cells. 5. The method of claim 1, wherein the suspension culture comprises a gluatmine-free culture medium. 6. The method of claim 5, wherein the suspension culture comprises a culture medium comprising 5% fetal bovine serum. 7. The method of claim 1, wherein the suspension culture comprises a culture medium having a pH of 7.2. 8. The method of claim 1, wherein the dissolved oxygen level of the suspension culture is maintained at 30% of saturation during the growing step (a). 9. The method of claim 1, wherein the growing step (a) comprises growing the recombinant cells in suspension culture in a roller bottle. 10. The method of claim 9, wherein the bioreactor is a 40 L bioreactor. 11. The method of claim 1, wherein the growing step (a) comprises growing the recombinant cells in suspension culture in a bioreactor. 12. The method of claim 11, wherein the bioreactor is a 5 L bioreactor. 13. A method for producing a fusion protein capable of binding VEGF, the method comprising: (a) incubating recombinant cells in T-225 cm.sup.2 flasks in culture medium at 37.degree. C. and 5% CO.sub.2 until the cells approach confluence; (b) transferring the cells from the T-225 cm.sup.2 flasks to roller bottles and incubating the cells at 37.degree. C. and 5% CO.sub.2 until the cells reach confluence; (c) transferring the cells from the roller bottles to a 5 L bioreactor and growing the cells in 3.5 L of suspension culture at 37.degree. C. until the cell density reaches 4.times.10.sup.6 cells/mL; (d) transferring the cells from the 5 L bioreactor to a 40 L bioreactor and growing the cells in suspension culture at 34.degree. C.; and (e) isolating the fusion protein from the suspension culture from the 40 L bioreactor by affinity chromatography, followed by size-exclusion chromatography; wherein the recombinant cells contain an expression vector comprising a nucleic acid molecule that encodes a fusion protein selected from the group consisting of Flt1D2.Flk1D3.Fc.DELTA.C1(a) (SEQ ID NO:12) and VEGFR1R2-Fc.DELTA.C1(a) (SEQ ID NO:16). 14. The method of claim 13, wherein the recombinant cells are CHO cells which constitutively express the fusion protein.

Details for Patent 8,647,842

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	11/18/2011		2019-06-08
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	08/16/2018		2019-06-08

International Patent Family for US Patent 8,647,842

Country	Patent Number	Estimated Expiration
Argentina	044938
Austria	293164
Austria	417928
Austria	427962